Vancouver, WA – CytoDyn, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it is currently accepting only 155 more candidates across the country for its Phase 2b/3 registrational trial in patients with severe-to-critical COVID-19. CytoDyn is currently enrolling COVID-19 patients in its Phase 2b/3 clinical trial in at […]